Tumor-Treating Fields Plus Temozolomide Versus Temozolomide Alone in Newly Diagnosed Glioblastoma: A Systematic Review and Bayesian Meta-Analysis with Meta-Regression
Cancers · 16.06.2026 · 18 (12) · 1947
DOI: 10.3390/cancers18121947 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 16.06.2026. Verfasst von Plamen Penchev und 8 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Medical University of Plovdiv, 4001 Plovdiv, Bulgaria. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Glioblastoma is the most aggressive primary brain tumor in adults, with limited survival despite multimodal therapy. Tumor-treating fields (TTFs) combined with temozolomide (TMZ) have emerged as a therapeutic option for newly diagnosed glioblastoma (nGBM), yet the magnitude, robustness, and generalizability of its benefit remain uncertain. This Bayesian meta-analysis aimed to determine whether the addition of TTFs to TMZ improves survival outcomes and safety profiles in patients with nGBM.
Methods
We systematically searched PubMed, Scopus, and the Cochrane Library from inception to 5 April 2026, for studies comparing TTFs + TMZ with TMZ alone in nGBM (PROSPERO “CRD420261374813”). Outcomes included overall survival (OS; hazard ratio [HR]), progression-free survival (PFS; HR), and dermatologic adverse effects (proportions). A Bayesian random-effects model with vague priors for overall effects and informative/weakly informative priors for between-study heterogeneity was applied. Sensitivity analyses with alternative prior specifications were performed, and posterior probabilities (PPs), 95% credible intervals (CrIs), and posterior predictive probabilities (PPPs) were estimated.
Results
Twelve studies (one randomized controlled trial and 11 observational studies) comprising 2797 patients were included (TTFs + TMZ: 1228; TMZ: 1569). TTFs + TMZ was associated with improved OS (HR 0.68; 95% CrI 0.57–0.80; 99% PP HR < 1) with a 96% PPP that future studies would also favor TTFs + TMZ. PFS was likewise improved (HR 0.67; 95% CrI 0.58–0.77; 99% PP HR < 1), with a 98% PPP favoring TTFs + TMZ in future studies. Subgroup analyses suggested that risk of bias contributed more to heterogeneity than study design. Among patients receiving TTFs + TMZ, the estimated proportion of dermatologic adverse effects was 57.8% (95% CrI 0.36–0.79), with high PPs of exceeding clinically meaningful thresholds.
Conclusions
In this Bayesian meta-analysis, TTFs combined with TMZ was associated with improved OS and PFS in nGBM, although dermatologic toxicity was frequent. These findings support TTFs + TMZ as an effective adjunctive strategy, while emphasizing the importance of patient selection, adherence, and toxicity management.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Medicine, Medical University of Plovdiv, 4001 Plovdiv, Bulgaria.
- Department of Pediatrics, St. George's University Hospital, 4002 Plovdiv, Bulgaria.
- Department of Anatomy, Histology and Embryology, Medical University of Sofia, 1431 Sofia, Bulgaria.
- Faculty of Medicine, Universidad Catolica de Santiago de Guayaquil, Guayaquil 090615, Ecuador.
- Clinic of Neurosurgery, University Hospital "St. Marina", 9010 Varna, Bulgaria.
- Faculty of Medicine, Medical University of Varna, 9002 Varna, Bulgaria.
ORCID-Profile: Plamen Penchev, Daniela Milanova-Ilieva, Lyubomir Gaydarski, Nikolai Ramadanov
Zitieren
APA
Penchev, P., Milanova-Ilieva, D., Gaydarski, L., Alonso-Vera, J. E., Stavrevski, S., Petrov, P. P., Noack, L., Ramadanov, N., & Suchorska, B. (2026). Tumor-Treating Fields Plus Temozolomide Versus Temozolomide Alone in Newly Diagnosed Glioblastoma: A Systematic Review and Bayesian Meta-Analysis with Meta-Regression. Cancers, 18(12), 1947. https://doi.org/10.3390/cancers18121947
Vancouver
Penchev P, Milanova-Ilieva D, Gaydarski L, Alonso-Vera JE, Stavrevski S, Petrov PP, et al. Tumor-Treating Fields Plus Temozolomide Versus Temozolomide Alone in Newly Diagnosed Glioblastoma: A Systematic Review and Bayesian Meta-Analysis with Meta-Regression. Cancers. 2026;18(12):1947. doi:10.3390/cancers18121947
BibTeX
@article{Penchev2026,
author = {Penchev, Plamen and Milanova-Ilieva, Daniela and Gaydarski, Lyubomir and Alonso-Vera, Jorge Eduardo and Stavrevski, Stefan and Petrov, Petar-Preslav and Noack, Laurens and Ramadanov, Nikolai and Suchorska, Bogdana},
title = {Tumor-Treating Fields Plus Temozolomide Versus Temozolomide Alone in Newly Diagnosed Glioblastoma: A Systematic Review and Bayesian Meta-Analysis with Meta-Regression},
journal = {Cancers},
year = {2026},
volume = {18},
number = {12},
pages = {1947},
doi = {10.3390/cancers18121947}
}
EUVIMED